Pharma News

Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.

- Read more about Health Ministry issues a notification for bringing the HIV/AIDS Act, 2017 in force
The Ministry of Health and Family Welfare has issued a notification for bringing the Human Immunodeficiency Virus and Acquired Immune Deficiency Syndrome (Prevention and Control) Act, 2017 in force from 10th September, 2018.
- Read more about Government banned 328 FDCs in the country
The Ministry of Health and Family Welfare has prohibited the manufacture for sale, sale or distribution for human use of 328 Fixed Dose Combinations (FDCs) with immediate effect. It has also restricted the manufacture, sale or distribution of six FDCs subject to certain conditions.
- Read more about NITI Aayog, Intel and TIFR collaborate to set up a Model International Center for Transformative AI (ICTAI)
NITI Aayog, Intel, and Tata Institute of Fundamental Research (TIFR) announced on 7th September that they are collaborating to set up a Model International Center for Transformative Artificial Intelligence (ICTAI) towards developing and deploying AI-led application-based research projects. This initiative is part of NITI Aayog’s ‘National Strategy for Artificial Intelligence’ Discussion Paper that focuses on establishing ICTAI in the country through private sector collaboration.
- Read more about Aurobindo acquired US Business of Sandoz
Aurobindo Pharma Limited a world-leading marketer and manufacturer of generic pharmaceuticals and active pharmaceutical ingredients, announces the signing of a definitive agreement to acquire certain assets from Sandoz Inc., USA ("Sandoz"), a Novartis Division, comprising a market leading dermatology business and a portfolio of oral solid products along with commercial and manufacturing infrastructure in the US. The acquisition will be on debt free and cash free basis and will be made through its wholly owned subsidiary, Aurobindo Pharma USA Inc. Aurobindo and Sandoz will enter into a transitional services agreement to support the ongoing growth plans of the businesses being acquired by Aurobindo.
- Read more about Pfizer got Breakthrough Therapy Designation from FDA for Alopecia Drug
Pfizer Inc announced its investigational oral Janus kinase 3 (JAK3) inhibitor PF-06651600 received Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA) for the treatment of patients with alopecia areata, a chronic autoimmune skin disease that causes hair loss on the scalp, face, or body.
- Read more about FDA approves new dosage strength of buprenorphine and naloxone sublingual film as maintenance treatment for opioid dependence
The U.S. Food and Drug Administration approved Cassipa (buprenorphine and naloxone) sublingual film (applied under the tongue) for the maintenance treatment of opioid dependence. This action provides a new dosage strength (16 milligrams/4 milligrams) of buprenorphine and naloxone sublingual film, which is also approved in both brand name and generic versions and in various strengths.
- Read more about Health ministry decide for renaming drug regulator CDSCO
The Union Health Ministry decide for renaming the country's drug regulator CDSCO in line with its expanded roles. In a public notice issued on 6.9.2018, the Central Drugs Standard Control Organisation(CDSCO) said its name was given keeping its role when it was created, but the present nomenclature was not reflecting its roles and responsibilities.
- Read more about FDA updated approach for including added sugar information on the Nutrition Facts labels of pure maple syrup and honey
Advancing better nutrition is one of my top priorities and implementing the update to the iconic Nutrition Facts label — the first overhaul in 20 years — is a key part of that commitment.

[adsense:336x280:8701650588]
- Read more about FDA new steps to help ensure the quality of and preserve access to compounded drugs by pursuing closer collaboration with states
The practice of compounding medicines can provide important public health opportunities. The FDA’s compounding program – including implementation of the compounding provisions of the law – is a priority for the agency.
- Read more about FDA global efforts to help assure product quality and transparency at foreign drug manufacturing facilities
Over the past 25 years, globalization of drug manufacturing has prompted the FDA to change its regulatory landscape. The shift to overseas production of U.S. goods, including some drugs and their components, predominantly occurred in the early 2000s. It added new complexities to our supply chain. This required the FDA to take different steps to ensure that our drug manufacturing surveillance program kept pace with the evolving landscape and make sure consumers continued to receive safe and effective drug products.